〔Abstract〕 Objective To explore a new MEK 1/2 inhibitor 3-(2,3-dihydroxypropyl)-6-fluor-5-((2-fluor-4-iodophenyl) amido)-8-methylpyridine[2,3-d] pyrimidine-4, 7(3 H, 8 H)-diketone(TAK-733) affects the biological behavior of human papillary thyroid carcinoma(PTC) TPC-1 cells. Methods TPC-1 cells with good growth and logarithmic growth were randomly divided into 2.5、5、10 μmol/L groups and control group, the proliferation ability of each group was detected by MTT assay after 24、48、72 h, respectively. The cell cycle and apoptosis of each group were detected by flow cytometry at 24、48 h, respectively. The migration of TPC-1 cells in each group after 24 h of action was detected by scratch healing test. Results Compared with the control group, TPC-1 cells treated with TAK-733 showed higher inhibition rate of proliferation in a time and dose dependent manner(P<0.05);the apoptosis rate of TPC-1 cells and the proportion of TPC-1 cell G1/G0in each group were higher than those in the control group(P<0.05) and the proportion of S and G2/M cells decreased(P<0.05),which showed an increase in time and dose dependence; the degree of scratch healing decreased in a concentration dependent manner(P<0.05). Conclusion TAK-733 can inhibit the proliferation and migration of human papillary thyroid carcinoma TPC-1 cells, block cell cycle and induce cell apoptosis.